Alcohol, Benzos, and Non-benzodiazepine sedative-hypnotics

0.0(0)
Studied by 1 person
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
full-widthPodcast
1
Card Sorting

1/29

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 7:25 PM on 10/14/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

30 Terms

1
New cards
<p>0.6 oz (14 g). This is 1.5 oz of 80 proof liquor, 5 oz wine, or 12 oz beer</p>

0.6 oz (14 g). This is 1.5 oz of 80 proof liquor, 5 oz wine, or 12 oz beer

Ounces of pure alcohol in a standard drink

2
New cards
<p>Inhibits <span style="color: red;"><strong>aldehyde dehydrogenase</strong></span> -&gt; 5-10x higher than normal levels of acetaldehyde-&gt; flushing, HA, n/v, cp, blurred vision, sweating, confusion, dyspnea, and anxiety. Starts approximately 10 minutes after alcohol and can last up to an 1 hour</p>

Inhibits aldehyde dehydrogenase -> 5-10x higher than normal levels of acetaldehyde-> flushing, HA, n/v, cp, blurred vision, sweating, confusion, dyspnea, and anxiety. Starts approximately 10 minutes after alcohol and can last up to an 1 hour

Mechanism of action of disulfram

3
New cards

Also bind the GABAA receptor, but chemical structure is NOT like benzos. These are the “Z-drugs" prescribed for insomnia, eg zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata)

Mechanism of action of non-benzodiazepine sedative-hypnotics

4
New cards

Both involve the emergence of symptoms for which the benzo was originally prescribed, but rebound is characterized by a HIGHER intensity than before treatment and is shorter in duration than symptom recurrence/relapse


What is the difference between symptom recurrence/relapse vs symptom rebound?

5
New cards
<p>Microcephaly, micrognathia (small jaw), low nasal bridge, and thin upper lip</p>

Microcephaly, micrognathia (small jaw), low nasal bridge, and thin upper lip

Features seen in Fetal Alcohol Syndrome (FAS)

6
New cards

OPRM1 gene (codes for the mu-opioid receptor)

Naltrexone for the treatment of AUD is more efficacious in patients with at least one copy of the Asp40 allele on this gene. Also has an effect on opioid dependence, HPA axis response to stress, sensitivity to pain, and responsiveness to analgesics. Asians are more commonly affected by this mutation.


7
New cards

GABRA2

Polymorphisms in this gene relates to the severity of alcohol withdrawal symptoms, high daily alcohol consumption, and extent of positive reinforcement with alcohol use in patients WITHOUT AUD

8
New cards
<p>Small intestine (This is why food = less absorption of alcohol [delays gastric emptying])</p>

Small intestine (This is why food = less absorption of alcohol [delays gastric emptying])

Area of the GI tract that has the highest rate of alcohol absorption

9
New cards

9

This NIAA recommends alcohol screening and brief intervention to start at this age

10
New cards
<p>Oxidation</p>

Oxidation

The process by which the liver metabolizes alcohol

11
New cards
<p>Ethyl sulfate (EtS) and ethyl gluconoride (EtG) are highly specific <strong>urine biomarkers</strong> of alcohol use</p><p></p><p>(They are not direct metabolites of alcohol, but are formed through enzymatic conjugation. <span style="color: red;"><strong>EtS is less prone to false positives so is more specific. </strong></span>S = specific)</p>

Ethyl sulfate (EtS) and ethyl gluconoride (EtG) are highly specific urine biomarkers of alcohol use


(They are not direct metabolites of alcohol, but are formed through enzymatic conjugation. EtS is less prone to false positives so is more specific. S = specific)

Which lab value is the most specific indicator of recent alcohol consumption? (Not BAC)

12
New cards

A9

This allele, which affects central dopamine function, is associated with the severity of alcohol withdrawal, including seizures and DTs

13
New cards

Michigan Alcoholism Screening Test-Geriatric Version (MAST-G)

Validated screening tool to assess for AUD in geriatric patients

14
New cards
<p>Note: CDT is the most accurate biomarker of recent heavy alcohol use </p>

Note: CDT is the most accurate biomarker of recent heavy alcohol use

Different biochemical markers of alcohol use

15
New cards

Drinker Inventory of Consequences (DrInc)

Measures the adverse consequences of alcohol use in five domains: physical, social, impulse, interpersonal, and intrapersonal

16
New cards

Minnesota Model

Believes that AUD is an involuntary, primary, chronic, and progressive biopsychosocial-spiritual disease. Drew on principles from AA.

17
New cards

ALDH1A1

Gene linked to epigenetic changes that occur in patients who have ACEs → alcohol misuse

18
New cards
  • Persons < 65 and women: 4 or more drinks daily / 7 drinks per week

  • Men: 5 or more drinks daily / 14 drinks per week


At risk drinking thresholds for women, men, and persons > 65

19
New cards

AUTS2

Gene involved in differences in human prefrontal cortex (handle reward, decision-making, and behavior) → lower activity → alcohol misuse

20
New cards

0.015 g/100mL/hour, which is the same as reducing your BAC level by 0.015 per hour. For people with chronic alcohol use, can increase to 0.02 per hour

Metabolism of alcohol per hour

21
New cards

ADH1B

Encodes alcohol dehydrogenase; variants yield changes in metabolism of alcohol → ↑ GI cancer

22
New cards
<p>T-ACE</p>

T-ACE

Alcohol screening tool validated in pregnant women

23
New cards

300-399

Blood alcohol level for hypothermia, dysarthria, amnesia, and stage I anesthesia

24
New cards

200-299

Blood alcohol level for obvious intoxication except for patients w/ tolerance - n/v and ataxia

25
New cards
  • 1-7 low risk consumption of alcohol

  • 8-14 harmful/hazardous use

  • 15 or more indicates alcohol dependence


The AUDIT, which has 10 questions and is developed by the WHO, is scored this way

26
New cards

Project MATCH

Compared patients with AUD randomly assigned to cognitive–behavioral therapy, motivational treatment, and 12-step facilitation. They all worked, but MET = more effective for angry patients/low motivation. 12 step = more effective for those with little support and severe AUD. CBT = more effective for less severe AUD

27
New cards

COMBINE study

Assessed patients with AUD on naltrexone, acamprosate, and combined behavioral intervention (CBI). Patients receiving medical management with naltrexone, CBI, or both fared better on drinking outcomes, whereas acamprosate showed no evidence of efficacy, with or without CBI

28
New cards

10%

12 month prevalence of AUD

29
New cards

12 hours. Reactions can persist up to 2 weeks

How long since last drink before starting disulfram?

30
New cards

Inhibits VTA neuronal activity due to increase GABA tone in the nucleus accumbens, antagonizes glutamate, and suppresses dopamine release in the nuclear accumbens reducing the reward aspects of alcohol use

How does topiramate treat AUD?